Page 19 - Test PDF v5

« Back to Contents OVARIAN CANCER

LiFE re

Literature for ENYGO

Hereditary ovarian cancer (BRCA1/2 mutation, genetic counselling,
management)

Relevant articles retrieved Nov 2015 - Feb 2016

No Title Authors Journal Link to abstract
Gynecol Oncol.
1 Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation Domchek SM et al. Cell Rep. http://www.ncbi.nlm.nih.gov/pub-
carriers with advanced ovarian cancer and three or more lines of prior therapy. J Cell Biol. med/26723501
Nat Med.
2 Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroR- Choi YE et al. Br J Cancer. http://www.ncbi.nlm.nih.gov/pub-
NA-622 in BRCA1-Mutant Ovarian Cancer. Br J Cancer. med/26774475
N Engl J Med.
3 TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determi- Moudry P et al. J Natl Compr Canc Netw. http://www.ncbi.nlm.nih.gov/pub-
nes PARP inhibitor sensitivity. Gynecol Oncol. med/26811421
Fam Cancer.
4 Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumour Du Y et al. Fertil Steril. http://www.ncbi.nlm.nih.gov/pub-
effects of PARP inhibitors. Gynecol Oncol. med/26779812
Oncotarget.
5 The development of PARP inhibitors in ovarian cancer: from bench to bedside. Drew Y Hered Cancer Clin Pract. http://www.ncbi.nlm.nih.gov/pub-
Int J Gynecol Cancer. med/26669452
6 PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment Ledermann JA
decisions. Hartmann LC et al. http://www.ncbi.nlm.nih.gov/pub-
med/26669450
7 The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
http://www.ncbi.nlm.nih.gov/pub-
8 Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. Daly MB et al. med/26840135

9 Germline BRCA1/2 testing practices in ovarian cancer: Current state and Lheureux S et al. http://www.ncbi.nlm.nih.gov/pub-
opportunities for new directions. med/26850485

10 The impact of an interventional counselling procedure in families with a Sermijn E et al. http://www.ncbi.nlm.nih.gov/pub-
BRCA1/2 gene mutation: efficacy and safety. med/26475959

11 Treatment of infertility does not increase the risk of ovarian cancer among Gronwald J et al. http://www.ncbi.nlm.nih.gov/pub-
women with a BRCA1 or BRCA2 mutation. med/26748927

12 Ten-year survival after epithelial ovarian cancer is not associated with BRCA Kotsopoulos J et al. http://www.ncbi.nlm.nih.gov/pub-
mutation status. med/26698676

13 BRCA somatic and germline mutation detection in paraffin embedded ovarian Mafficini A et al. http://www.ncbi.nlm.nih.gov/pub-
cancers by next-generation sequencing. med/26556769

14 Clinical features and outcomes of germline mutation BRCA1-linked versus Synowiec A et al. http://www.ncbi.nlm.nih.gov/pub-
sporadic ovarian cancer patients. med/26745875

15 Clinical and Pathological Characteristics of Incidental Diagnostic Early Occult Lavie O et al. http://www.ncbi.nlm.nih.gov/pmc/
Malignancy After Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation articles/PMC4706695/
Carriers.
http://www.ncbi.nlm.nih.gov/pub-
med/26807561

16 Clinical Practice Guideline for the prevention and early detection of breast and Singer CF et al. Wien Klin Wochenschr. http://www.ncbi.nlm.nih.gov/pub-
ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) med/26525377
families.

17 Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Eccles DM et al. Adv Ther. 2016 Jan 25. http://www.ncbi.nlm.nih.gov/pub-
Findings from Guidelines and a Systematic Literature Review. med/26809252

International Journal of Gynecological Cancer, Volume 26, Supplement #1 Page 19